Rewalk Robotics Ltd is a company specializing in the development and commercialization of exoskeleton systems that assist individuals with mobility impairments. Their business model revolves around offering innovative solutions to enhance the quality of life for people with spinal cord injuries, stroke survivors, and other neurological conditions. With a focus on research, development, and production of their robotic exoskeletons, Rewalk Robotics aims to improve mobility, independence, and overall well-being for individuals facing mobility challenges. By combining advanced technology and extensive medical expertise, Rewalk Robotics Ltd strives to be at the forefront of the assistive device industry, providing life-changing solutions for those in need.

Rewalk Robotics Ltd is primarily active in the healthcare and medical device industry.

Rewalk Robotics Ltd faces competition from various companies in the market. Some of its main competitors include Ekso Bionics Holdings, Inc., Parker Hannifin Corporation, and Rex Bionics PLC. These competitors also focus on developing and providing innovative robotic exoskeleton solutions and rehabilitation technologies. However, Rewalk Robotics Ltd continues to stand out by leveraging its unique patented designs and advanced functionalities, catering to the specific needs of individuals with mobility impairments.

Rewalk Robotics Ltd is a leading innovative medical device company that designs and develops wearable robotic exoskeletons to help individuals with lower limb disabilities regain their mobility. Founded in 2001, Rewalk Robotics has been dedicated to transforming the lives of people with spinal cord injuries, allowing them to walk again with greater independence. The company's advanced technology combines artificial intelligence, motion sensors, and motorized systems to provide users with enhanced mobility and improved quality of life. Rewalk Robotics has gained global recognition for its groundbreaking solutions and continues to strive for advancements in the field of robotic rehabilitation.

Rewalk Robotics Ltd has achieved several significant milestones since its inception. One of the notable accomplishments is the development and commercialization of their exoskeleton technology, revolutionizing the lives of individuals with lower limb disabilities. The company has successfully obtained regulatory approvals for their innovative designs in various regions, enabling broader market access. Additionally, Rewalk Robotics Ltd has formed strategic partnerships with leading healthcare providers and institutions, fostering collaborations to improve patient outcomes. These milestones highlight the company's commitment to advancing the field of robotics for functional mobility and improving the quality of life for individuals with mobility impairments.

Rewalk Robotics Ltd is primarily present in several countries and regions across the world. The company has a global presence and operates in various key markets, including the United States, Europe, Asia, and beyond. With its cutting-edge assistive technologies for individuals with mobility impairments, Rewalk Robotics Ltd has made significant strides in expanding its reach internationally. The company's commitment to improving the lives of individuals with spinal cord injuries and other mobility challenges has garnered recognition and adoption across different parts of the globe.

Rewalk Robotics Ltd represents values of innovation, determination, and commitment to improving the lives of individuals with lower limb disabilities. The company's corporate philosophy revolves around creating advanced robotic exoskeletons that enable individuals to walk again. By incorporating cutting-edge technology and continuous research and development, Rewalk Robotics strives to enhance mobility, increase independence, and improve overall quality of life for its users. Through a strong focus on user-centric design and collaboration with medical professionals, Rewalk Robotics Ltd aims to provide effective and personalized solutions to help individuals regain their independence and reintegrate into society.

Analysts currently set an average price target of 7,40 USD for the Lifeward stock (median: 7,40 USD), implying +2,4 % versus the latest price. The consensus is based on 8 analyst ratings.

Lifeward Analyytikkojen kursstavoitteet 2026

8 analysts currently rate the Lifeward stock: 7 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Lifeward to generate revenue of 43,63 M USD and earnings per share of −6,70 USD.

Lifeward Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Lifeward share trades at 6,14 EUR (7,07 USD).

The Lifeward share (LFWD) is listed on 3 stock exchanges, including: NASDAQ (RWLK), Frankfurt (2RW.F), München (2RW.MU).

Rewalk Robotics Ltd is a leading company in the development of robotics technologies that assist people with reduced mobility capabilities. The company is based in Yokneam, Israel, and was founded in 2001. The company operates in several sectors, including the medical and rehabilitation industry, the military and security industry, and the leisure and entertainment industry. The main product of Rewalk Robotics is the ReWalk Rehabilitation Exoskeleton suit. This state-of-the-art suit allows people with spinal cord injuries to stand and walk again. The suit supports the user's limbs and improves their posture and mobility. The product has been very successful in the medical and rehabilitation industry, as it provides people with greater independence and improved self-confidence. Rewalk Robotics also has a military and security-oriented division. The company is currently developing a range of robots that can be used in emergency situations, disaster relief, or combat zones. The robots can perform tasks such as intercom systems, weapon transport, remote control of vehicles, and much more. This division of the company is rapidly growing and has a lot of potential. Another important area of Rewalk Robotics is the leisure and entertainment industry. The company offers a variety of products that help people with mobility issues to participate in sports and other physical activities. These include racing wheelchairs, adaptive sports clothing, and much more. Rewalk Robotics is known for its innovation and has received a number of awards in recent years. The company is constantly striving to improve its products and has been successful in doing so. It has a broad customer base and works closely with governments, healthcare institutions, and other companies to bring its products to market. Overall, Rewalk Robotics has a successful business model that targets the needs of people with mobility issues. The company has a clear vision and is constantly working to improve its products to achieve the best results. With advancing technology and an increasing demand for mobility solutions, the company has enormous growth opportunities and will play an important role in the future.

odotettu liikevaihto Lifeward on 43,63 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Lifeward on −4,85 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Lifeward:n hinta-voitto-suhde (P/E) on tällä hetkellä −1,06. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Lifeward-osakkeen arvostusta.

Lifeward:n hinta-myynti-suhde (P/S) on tällä hetkellä 0,12. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Lifeward-osakkeen arvostuskennuslukuna.

Lifeward:n Eulpool-laatuscore on 4/10.

Lifeward:n ISIN on IL0011331076. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Lifeward:n WKN on A12BMB. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Lifeward:n ticker on LFWD. Tämä pörssinoteeraus käytetään Lifeward-osakkeiden kauppaan pörssissä.

Lifeward maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Lifeward kuuluu sektoriin 'Terveydenhuolto'.

Lifeward:n osingot jaetaan valuutassa USD.